NBS Present at Multiple Conferences in November NEW

New Post Public Reply Private Reply Replies (1) Message Board

Nov 2, 2012 at 9:42 AM

[b]NBS >> Present at Multiple Conferences in November[/b]

NEW YORK, Oct. 31, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), an emerging leader in the fast growing cell therapy market, today announced that Company management and management of its subsidiary, Progenitor Cell Therapy ("PCT"), have been invited to present at multiple conferences in November.

American Heart Association – Scientific Sessions 2012

Date: November 6, 2012, 11:00 AM PST
Venue: Los Angeles Convention Center, Los Angeles, CA
Session Title: Cardiovascular Regeneration: From Bench to Clinic
Presenter: Jonathan Sackner-Bernstein, M.D., FACC, Vice President, Clinical Development and Regulatory Affairs of NeoStem will present an abstract titled "Predictors of Response to Intracoronary Delivery of CD34+CXCR4+ Enriched Bone Marrow Derived Stem Cells (AMR-001) Early After STEMI"
2012 ISPE Annual Meeting: Global GMP Solutions through Innovation and Transformation

Date: November 12, 2012, 3:30 PM PST
Venue: Marriott Marquis, San Francisco, CA
Presenter: Sanjin Zvonic, Ph.D., Director of Technology and Business Development of PCT, will speak on "Immunotherapies and Tissue Culture Manufacturing Technologies" within the Biotechnology Executive Series Session
Lazard Capital Markets 9th Annual Healthcare Conference

Date: November 14, 2012, 10:00 AM EST
Venue: The Pierre Hotel, New York, NY
Presenter: Robin L. Smith, M.D., M.B.A., Chairman and CEO of NeoStem will give a company presentation.
New York Society of Security Analysts' 16th Annual "Investing in Life Sciences" Conference

Date: November 29, 2012, 11:15 AM EST
Venue: NYSSA Conference Center, New York, NY
Presenters: Robin L. Smith, M.D., M.B.A., Chairman and CEO of NeoStem will give a company presentation.
About NeoStem, Inc.

NeoStem, Inc. continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy market. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC ("PCT"), with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe this expertise and existing research capabilities and collaborations will enable us to achieve our mission of becoming a premier cell therapy company.

Our contract development and manufacturing service business supports the development of proprietary cell therapy products. NeoStem's most clinically advanced therapeutic, AMR-001, is being developed at Amorcyte, LLC ("Amorcyte"), which we acquired in October 2011. Amorcyte is developing a cell therapy for the treatment of cardiovascular disease and is enrolling patients in a Phase 2 trial to investigate AMR-001's efficacy in preserving heart function after a heart attack. Athelos Corporation ("Athelos"), which is approximately 80%-owned by our subsidiary, PCT, is collaborating with Becton-Dickinson in the early clinical exploration of a T-cell therapy for autoimmune conditions. In addition, pre-clinical assets include our VSELTM Technology platform as well as our mesenchymal stem cell product candidate for regenerative medicine. Our service business and pipeline of proprietary cell therapy products work in concert, giving us a competitive advantage that we believe is unique to the biotechnology and pharmaceutical industries. Supported by an experienced scientific and business management team and a substantial intellectual property estate, we believe we are well positioned to succeed.

For more information, please visit www.neostem.com.

Forward-Looking Statements for NeoStem, Inc.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's or its partners' successful development of AMR-001 and other cell therapeutics, the size of the market for such products, its competitive position in such markets, the Company's ability to successfully penetrate such markets and the market for its contract development and manufacturing ("CDMO") business, and the efficacy of protection from its patent portfolio, as well as the future of the cell therapeutics industry in general, including the rate at which such industry may grow. Forward looking statements also include statements with respect to satisfying all conditions to closing the disposition of Erye, including receipt of all necessary regulatory approvals in the PRC. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including but not limited to matters described under the "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 20, 2012 and in the Company's other periodic filings with the Securities and Exchange Commission, all of which are available on its website. The Company does not undertake to update its forward-looking statements. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

Trout Group
Gitanjali Jain Ogawa, Vice President
Phone: +1-646-378-2949
Email:

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Atlas-SSI Expands Grip in Water Control Space

Atlas-SSI Makes Waves with Linita Acquisition Here's the kind of news that makes an old market hound sit up and take notice. Atlas-SSI, the big cheese in North America for water management solutions, has gone and snagged Linita Design & Manufacturing. Why's this worth talking about? Linita isn't just any player—they've been crafting custom-engineered hydro-mechanical...

Q32 Bio Eyes New Horizons with Bempikibart's Potentials

Q32 Bio Steers Forward: New Insights from Chief Results Today's update isn't just another quarterly snooze-fest—it’s a nudge in a crucial direction for Q32 Bio (NASDAQ:QTTB). After a bold brush with the European Academy of Dermatology and Venereology (EADV) Congress 2026, the company laid out a plan and a half, showing its hand with bempikibart for alopecia areata...

MY DR NOW Expands: Seven-Day Clinics Open Everywhere

Breaking The Mold Of Traditional Medicine MY DR NOW isn't here to play by the age-old rules. They're slinging open the doors to their newest family medicine clinics and kicking the old Monday-to-Friday scheduling straight to the curb. Every single day of the week, from 8 a.m. to 8 p.m., patients in Sunnyvale and Tucson are getting a dose of healthcare that's all about...

DarioHealth Taps Palumbo to Drive Healthcare Evolution

Strategic Leadership for an Evolving Market Prepare your portfolios, folks. DarioHealth Corp. (NASDAQ:DRIO) is gearing up to ride a seismic shift in healthcare. John R. Palumbo's appointment as Chairman of the Board marks a bold move as Dario looks to dominate the new convergence of consumer-directed and payer-funded healthcare. This isn't just a change of guard; it's a...

Hyundai Pushes Hydrogen Boundaries at 2026 Expo

A Bold Step Into the Hydrogen Era Hyundai's really stepping it up at the World Hydrogen Expo 2026. They're not just dipping their toes in the hydrogen pool—they're diving in headfirst, showing off integrated hydrogen solutions that are nothing short of ambitious. Hydrogen Production That's a Real Game Changer This ain't just talk. Hyundai's showcasing modular PEM...

Greasezilla to Process 15M Gallons of FOG Yearly

Greasezilla Steps Up for FOG Processing If there’s one thing that makes dealing with wastewater a greasy business, it’s FOG - fats, oils, and grease. It’s the stuff nightmares are made of for any utility trying to keep their pipes clear and their operations running smooth. Now, Greasezilla is stepping into the spotlight at one of the country's largest wastewater...

Natixis' $100M Student Challenge Mixes Real Stakes

Opportunity Knocks for Budding Portfolio Managers Picture this: You're a student, neck-deep in textbooks and theories, and then bam! You're handed the keys to manage a $100 million portfolio. That's the real-deal opportunity Natixis Investment Managers is dangling with its seventh Students Challenge. Diving Into the Nuts and Bolts Listen up, kids. Applications are open...

Camtek Hits Record Q3 Revenue; Strong Growth Ahead

Camtek's Record Performance in Q3 2026 Diving straight into the numbers, Camtek (NASDAQ:CAMT) just posted a staggering $161.3 million in Q3 2026 revenues, marking a 21% jump from the previous quarter. Now, that kind of growth isn't just impressive; it's a wake-up call to any investor still snoozing on semiconductor stocks. They're looking at revenues of around $180...

Sinch Partners with SpaceX's Super Intelligence Network

Piecing Together the New Sinch and SpaceX Partnership Here's a juicy piece of tech news that might just tickle those investing antennas: Sinch AB's teaming up with the SpaceX Super Intelligence Network as a Marketplace Partner. Let's rip the Band-Aid off about why this development has investors riled and buzzing with expectation. Now, Sinch might not be the first company...

Askey & Icom Team Up: Trading Airwaves for Partnerships

Old-School Radios Meet Cutting-Edge 5G When I hear about a company linking their old-school tech with shiny new 5G jazz, skepticism kicks in fast. But then comes this announcement: Askey and Icom America are joining forces to bring 5G networks with integrated two-way radio systems to various sectors—like a classic combo meal with a tech twist. The key audience? Utility...